The Anorexia Nervosa Market Size is Expected to Grow at a Significant CAGR of 18.9% in the 7MM During the Study Period (2019-32)

The overall Anorexia Nervosa market is expected to boost due to rising prevalence cases over the globe and thus the surge in treatment options. Along with the expected launch of emerging therapy in the Anorexia Nervosa treatment market can boost during the forecasted period (2022–2032)

LAS VEGAS, May 16, 2022 /PRNewswire/ -- DelveInsight's Anorexia Nervosa Market Insights report provides a comprehensive understanding of current treatment practices, Anorexia Nervosa emerging drugs, market share of individual therapies, and current and forecasted Anorexia Nervosa market size from 2019 to 2032, segmented into 7MM (the United States, the EU5 (the United Kingdom, Italy, Spain, France, and Germany), and Japan.

Key Takeaways from the Anorexia Nervosa Market

• As per DelveInsight's estimates, the Anorexia Nervosa market size was USD 63 million in 2021 which is further expected to increase by 2032 in the 7MM.
• As per analysis, the total Anorexia Nervosa prevalent cases in the 7MM were found more than 1.6 million in 2021.
• The leading Anorexia Nervosa companies such as COMPASS Pathways, Benuvia Therapeutics, Artelo Biosciences, RaQualia Pharma, Receptor Life Sciences, AstraZeneca, Pfizer, Homeostasis Therapeutics, LLC, and others are evaluating Anorexia Nervosa drugs in various stages of development that will launch in the Anorexia Nervosa market in the coming years.
• Key Anorexia Nervosa therapies in the pipeline include Psilocybin, RQ 00433412, ART 2713, PF-07258669, Ketamine, expected to bring a positive shift in the Anorexia Nervosa market along with others.
• The expected launch of therapies and the increasing prevalence will lead to Anorexia Nervosa market growth during the forecasted period. 

For further information on how the emerging therapies would shift the Anorexia Nervosa market landscape download the sample @ Anorexia Nervosa Market Outlook

Anorexia Nervosa Overview

Anorexia Nervosa is an eating disorder characterized by weight loss (or a failure to gain weight in growing children), difficulties maintaining a healthy body weight for one's height, age, and stature, and, in many cases, a distorted body image. Anorexics often restrict their calorie intake and the types of foods they eat.

The exact Anorexia Nervosa causes are unknown. However, genetic risk factors, as well as a mix of environmental, social, and cultural variables, may all play a role. It's possible that certain personality traits make some people more susceptible to anorexia than others.

The physical Anorexia Nervosa symptoms are connected to malnutrition. Anorexia also encompasses mental and behavioural disorders such as an inaccurate sense of body weight and an exceedingly intense fear of gaining weight or becoming obese. It may be difficult to detect symptoms of Anorexia Nervosa because what constitutes a low body weight varies from person to person, and some people may not seem particularly thin. In addition, persons suffering from anorexia frequently conceal their thinness, eating habits, or health difficulties. The Anorexia Nervosa diagnosis includes physical exams, lab tests, psychological evaluation, X-ray, ECG, and others.

Anorexia Nervosa Epidemiology Segmentation

As per DelveInsight, the total Anorexia Nervosa prevalent cases were approximately 1.6 million cases in the 7MM in 2021.

Among EU5 countries, Germany has the highest Anorexia Nervosa diagnosed prevalence, while Spain had the lowest in 2021.

The Anorexia Nervosa Market Report proffers epidemiological analysis for the study period 2019-2032 in the 7MM segmented into:

• Prevalent cases of Anorexia Nervosa
• Diagnosed prevalent cases of Anorexia Nervosa
• Gender-specific Prevalence of Anorexia Nervosa

Know how the epidemiological trends are going to look like in 2032 for the 7MM by downloading @ Anorexia Nervosa Epidemiological Insights

Anorexia Nervosa Treatment Market

Treatment typically entails a combination of methods, such as psychiatric therapy, dietary counselling, and/or hospitalization. Anorexia Nervosa treatment programs are tailored to the needs of the person and may involve one or more of the following:

• The individual, group, and/or family psychotherapy
• Medical care and monitoring
• Nutritional counselling
• Medications

Family-based treatment (FBT), eating disorder-focused psychotherapy, adolescent-focused psychotherapy, and other treatments are examples of psychotherapies. Antidepressants, antipsychotics, and mood stabilizers may also be beneficial in the treatment of eating disorders and other co-occurring conditions like anxiety or depression. Anorexia Nervosa treatment must address both psychological and physical issues. A mental health expert and a primary care doctor should be part of the therapy team.

Continuous medical care, frequent therapy, dietary counselling, and medication are typically required for successful Anorexia Nervosa treatment. Although certain antidepressants are used to treat anorexia, they are not always successful, and no drugs for Anorexia Nervosa have been authorized by the FDA. Patients are often managed with Anorexia Nervosa medications such as olanzapine, aripiprazole, and dronabinol, although there is no standard therapy available. Quetiapine is an atypical antipsychotic that, when taken in modest doses, can aid with both psychological and physical benefits while causing few side effects, making it a good contender for Anorexia Nervosa treatment. Prozac can aid with depression symptoms as well as potentially with healthy weight maintenance if weight loss has been accomplished.

Discover more about Anorexia Nervosa drug treatment @ Antipsychotic Drugs for Anorexia Nervosa Treatment

Anorexia Nervosa Pipeline Therapies and Key Companies

• RQ 00433412: RaQualia Pharma
• ART 2713: AstraZeneca
• PF-07258669: Pfizer
• Psilocybin: COMPASS Pathways
• Ketamine: Homeostasis Therapeutics

Discover more about therapy set to grab substantial Anorexia Nervosa market share @ Drugs for Anorexia Nervosa 

Anorexia Nervosa Market Dynamics

The growing prevalence of Anorexia Nervosa and the increasing number of cases globally are anticipated to result in an increase in treatment choices. As a result, the Anorexia Nervosa market will see an increase in the following year. Moreover, most guideline recommendations encourage using drug therapy in conjunction with psychotherapies, drug development companies can create novel treatment packages that comprise both drugs and psychotherapies, which further boosts the Anorexia Nervosa market. In addition, the collaboration between research institutes and pharmaceutical companies will also contribute to the growth of the Anorexia Nervosa market. 

However, certain factors are impeding the growth of the Anorexia Nervosa market. One of the main reasons is that there is a scarcity of trainers or experts to talk to patients and spread awareness among the population regarding Anorexia Nervosa. These are the major barriers to the Anorexia Nervosa market growth. Another major challenge to the Anorexia Nervosa market is the patients' social stigma and the unwillingness to accept their condition. Moreover, insufficient and unclear data to estimate the accurate Anorexia Nervosa cases are also limiting the growth of the Anorexia Nervosa market. In addition, lack of resources and funding are also acting as a barrier to the Anorexia Nervosa market growth. Furthermore, guidelines and recommendations are focused on non-pharmacological therapies, and thus impeding the growth of the Anorexia Nervosa market.

Know more about which pharma player in the Anorexia Nervosa market is set to emerge as the trendsetter @ Anorexia Nervosa Companies

Scope of the Anorexia Nervosa Market Report

• Study Period: 2019-2032
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Anorexia Nervosa Companies: COMPASS Pathways, Benuvia Therapeutics, Artelo Biosciences, RaQualia Pharma, Receptor Life Sciences, AstraZeneca, Pfizer, Homeostasis Therapeutics, LLC, and others
• Key Pipeline Therapies: RQ 00433412, ART 2713, PF-07258669, Psilocybin, Ketamine, and others
• Therapeutic Assessment: Anorexia Nervosa current marketed and emerging therapies
• Anorexia Nervosa Market Dynamics:  Anorexia Nervosa market drivers and barriers 
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Unmet Needs, KOL's views, Analyst's views, Anorexia Nervosa Market Access and Reimbursement

Discover more about the future Anorexia Nervosa market share of treatment therapies @ Drugs used to treat Anorexia Nervosa

Table of Contents

Get in touch with our Business executive @ Healthcare Due Diligence Services 

Related Reports

Anorexia Pipeline 

Anorexia Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Anorexia companies involved such as Amgen, COMPASS Pathways, Benuvia Therapeutics, among others.

Anorexia Epidemiology Forecast

Anorexia Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Anorexia epidemiology in the 7MM.

Cancer Anorexia Market

Cancer Anorexia Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cancer Anorexia companies such as Par Pharmaceutical, Helsinn Therapeutics, PRA Health Sciences, among others.

Cancer Anorexia-Cachexia Syndrome Market

Cancer Anorexia-Cachexia Syndrome Market Insights, Epidemiology, and Market Forecast-2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Cancer Anorexia-Cachexia Syndrome companies such as Xinqiao Hospital of Chongqing, Chengdu University of Traditional Chinese Medicine, Phramongkutklao College of Medicine and Hospital, among others.

Cancer Anorexia Epidemiology Forecast

Cancer Anorexia Epidemiology Forecast to 2032 report delivers an in-depth understanding of the disease, historical, and forecasted Cancer Anorexia epidemiology in the 7MM.

Obesity Pipeline

Obesity Pipeline Insight, 2022 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Obesity companies involved such as Novartis, Eli Lily &Company, Scohia Pharma, among others.

Other Trending Reports 

Hepatitis A Market

"Hepatitis A Market" research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Hepatitis A market size, share, and trends in 7MM. Some of the key companies in the Hepatitis A Therapeutics Market include Boryung Pharmaceutical, Cadila Healthcare, Indian Immunologicals, Biological E Limited, and others

Granulomatosis With Polyangiitis Market

"Granulomatosis With Polyangiitis Market" research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Granulomatosis With Polyangiitis market size, share, and trends in the 7MM. The key companies in the Granulomatosis With Polyangiitis Therapeutics Market include InflaRx GmbH, Bristol-Myers Squibb, Hoffmann-La Roche, and others.

Atopic Dermatitis Market 

"Atopic Dermatitis Market" research report provides a detailed overview of the disease, historical and forecasted epidemiology as well as the Atopic Dermatitis market size, share, and trends in the 7MM. The key companies in the Atopic Dermatitis Therapeutics Market include Abbvie, Eli Lily, Galderma, Onenss Biotech, LEO Pharma, Arena Pharmaceuticals, AOBiome Therapeutics, Pfizer, and several others. 

Hypertrophic Scar Market

"Hypertrophic Scar Market" research report delivers an in-depth understanding of the Hypertrophic Scar, historical and forecasted epidemiology as well as the Hypertrophic Scar market size, share, and trends in the 7MM. The key companies in the Hypertrophic Scar Therapeutics Market include Henry Ford Health System, Gladerma, Phio Pharmaceuticals, and others.

Secondary Hyperparathyroidism Market

"Secondary Hyperparathyroidism Market" research report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the Secondary Hyperparathyroidism market size, share, and trends in the 7MM. The key companies in the Hypertrophic Scar Therapeutics Market include Sanwa Kagaku Kenkyusho, OPKO Health, TaiRx, Amgen, and others.

Related Healthcare Blogs

Cancer Anorexia Market

Eating Disorders Market Landscape

About DelveInsight

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.  Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Connect With Us at LinkedIn | Facebook | Twitter

Contact Us

Shruti Thakur 
info@delveinsight.com  
+1(919)321-6187  
www.delveinsight.com

Logo: https://mma.prnewswire.com/media/1082265/DelveInsight_Logo.jpg

SOURCE DelveInsight Business Research, LLP